Interleukin-6 signalling, lipoprotein (a) lowering and cardiovascular disease: a mendelian randomisation study

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Stephen Brennan

Mater Misericordiae University Hospital, Dublin (Ireland)

5 More presentations in this session

Presentation thumbnail

Comparative efficacy of colchicine and intensive LDL-C lowering in patients with ASCVD receiving statins: a network meta-analysis of randomised controlled trials

Doctor Z. Ou (Chongqing, CN)

Abstract Slides Video

Presentation thumbnail

Deciphering lipoprotein(a) atherogenicity with use of high-throughput proteomics

Doctor J. Morze (Gothenburg, SE)

Abstract Slides Video

Presentation thumbnail

The upfront lipid-lowering combination therapy of statins and ezetimibe vs statin monotherapy in the reduction of cardiovascular outcomes. A meta-analysis.

Professor M. Banach (Lodz, PL)

Abstract Slides Video

Presentation thumbnail

Contemporary LDL-cholesterol management in male and female patients at high-cardiovascular risk: results from the European observational SANTORINI study

Professor D. Nanchen (Lausanne, CH)

Abstract Slides Video

Presentation thumbnail

The change of paradigm: high HDL-c levels could not mean a long lifespan

Doctor F. Sousa (Funchal, PT)

Abstract Slides Video

Access the full session

Session thumbnail

Dyslipidaemia: novel diagnostics and therapy options

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Congress Presentation

Lipid control in cardiovascular patients

Congress Presentation

Fix the plaque, fight the lipids: why low-density lipoproteins still matter after percutaneous coronary intervention

Congress Presentation

What’s new in LDL lowering?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources